Malcolm Salter Biography and Net Worth

Director of C4 Therapeutics

Malcolm Salter has served as a member of the Board of Directors since December 2015. Malcolm is the James J. Hill Professor, Emeritus, at the Harvard Business School. Since joining the Harvard Business School faculty in 1967, his teaching and research has focused on issues of corporate strategy and governance. He currently serves on the boards of directors of NextRNA, Inc., a biotechnology company focused on developing the next generation of RNA-directed therapeutics, since February 2021, and Raqia Therapeutics, Inc., a CAR-T cell therapies company for cancer and other diseases, since September 2020. From 1986 to 2006, he served as president of Mars & Co., a global strategy-consulting firm. He is a Trustee of the Dana-Farber Cancer Institute. Mr. Salter holds an A.B., M.B.A., and a D.B.A. from Harvard University.

What is Malcolm Salter's net worth?: The estimated net worth of Malcolm Salter is at least $17,910.32 as of August 20th, 2021. Mr. Salter owns 13,672 shares of C4 Therapeutics stock worth more than $17,910 as of April 7th. This net worth evaluation does not reflect any other assets that Mr. Salter may own. Learn More about Malcolm Salter's net worth.
How do I contact Malcolm Salter?: The corporate mailing address for Mr. Salter and other C4 Therapeutics executives is , , . C4 Therapeutics can also be reached via phone at 617-231-0700 and via email at jane.urheim@sternir.com. Learn More on Malcolm Salter's contact information.
Has Malcolm Salter been buying or selling shares of C4 Therapeutics?: Malcolm Salter has not been actively trading shares of C4 Therapeutics during the last quarter. Most recently, Malcolm Salter sold 755 shares of the business's stock in a transaction on Friday, December 17th. The shares were sold at an average price of $30.25, for a transaction totalling $22,838.75. Learn More on Malcolm Salter's trading history.
Who are C4 Therapeutics' active insiders?: C4 Therapeutics' insider roster includes Adam Crystal (Insider), Stewart Fisher (Insider), Elena Prokupets (Director), Malcolm Salter (Director), and Jolie Siegel (Insider). Learn More on C4 Therapeutics' active insiders.
Are insiders buying or selling shares of C4 Therapeutics?: In the last year, insiders at the sold shares 2 times. They sold a total of 1,159 shares worth more than $3,650.85. The most recent insider tranaction occured on February, 18th when insider Scott N Boyle sold 669 shares worth more than $2,107.35. Insiders at C4 Therapeutics own 8.6% of the company. Learn More about insider trades at C4 Therapeutics.
Information on this page was last updated on 2/18/2025.

Malcolm Salter Insider Trading History at C4 Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/17/2021	Sell	755	$30.25	$22,838.75
11/19/2021	Sell	755	$40.11	$30,283.05
10/15/2021	Sell	755	$44.94	$33,929.70
8/20/2021	Sell	755	$40.73	$30,751.15	13,672
7/16/2021	Sell	755	$37.37	$28,214.35	14,427
6/18/2021	Sell	755	$37.19	$28,078.45	14,843
5/21/2021	Sell	755	$37.12	$28,025.60	15,598

Malcolm Salter Buying and Selling Activity at C4 Therapeutics

C4 Therapeutics Company Overview

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $1.31

$1.27

$1.37

50 Day Range

MA: $2.61

$1.31

$3.68

2 Week Range

Now: $1.31

$1.27

$8.08

Volume

1,125,016 shs

Average Volume

1,396,129 shs

Market Capitalization

$93.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.11